Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high

Author(s): Grigg, S; Minson, A; Prins, E; Dickinson, MJ;
Details: Publication Year 2024-07,Volume 205,Issue #1,Page 122-126
Journal Title: British Journal of Haematology
Publication Type: Research article
Abstract: We reviewed cases with aggressive B-cell non-Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non-CD20-directed treatments in this cohort.
Publisher: Wiley
Keywords: Humans; *Antigens, CD20; Male; Female; Middle Aged; Aged; Prognosis; *Antibodies, Bispecific/therapeutic use; Recurrence; Adult; Aged, 80 and over; Lymphoma, B-Cell/mortality/drug therapy; immunotherapy; lymphoid malignancies; lymphomas
Department(s): Clinical Haematology
Publisher's Version: https://doi.org/10.1111/bjh.19455
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-01 05:00:17

Last Modified: 2024-08-01 05:00:43